Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | FPR3 | P25089 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326285 | 0.86 | CYP1A2 (0.39) | CYP2D6CYP1A2ALOX15CACNA1HDRD2 | |
| SCHEMBL29326319 | 0.85 | CACNA1H (0.55) | CACNA1HDRD2MEN1KMT2A | |
| SCHEMBL29324714 | 0.82 | CYP2D6 (0.42) | CYP2D6CYP1A2ALOX15HTTFPR3 | |
| SCHEMBL8136732 | 0.80 | OPRD1 (0.43) | CYP2D6CACNA1HDRD2NPC1NPSR1 | |
| SCHEMBL29326474 | 0.79 | ITGB3 (0.43) | CYP2D6CYP1A2ALOX15OPRD1 | |
| SCHEMBL31011765 | 0.79 | NPC1 (0.44) | CYP2D6DRD2NPC1NPSR1MEN1 | |
| SCHEMBL29324706 | 0.77 | CYP2D6 (0.37) | CYP2D6CYP1A2ALOX15CACNA1H | |
| SCHEMBL29326374 | 0.77 | ALOX15 (0.45) | CYP2D6CYP1A2ALOX15KMT2AHTT | |
| SCHEMBL29324697 | 0.75 | CYP1A2 (0.46) | CYP2D6CYP1A2ALOX15DRD2 | |
| SCHEMBL29326427 | 0.74 | ITGB3 (0.42) | CYP2D6CYP1A2ALOX15CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | CYP2D6 4042/4885CYP1A2 3232/4885ALOX15 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.